Alliance Pharma, a contract research organization, recently announced it plans to open a 20,000-square-foot bioanalytical laboratory in Brisbane, Australia, to support the company’s preclinical and clinical testing.
The Alliance Pharma Pty facility will be fully operational in November and will contain a lab focused on small and large molecule bioanalytical services.
The lab is equipped with technology that will allow a team of scientists to conduct early and late phase research and de novo method development, method transfers, method validation, and sample analysis for pharmacokinetic, biomarkers, and immunogenicity.
The facility will allow the company to transfer methods and maintain continuous project management across its bioanalytical sites in Europe and the United States.
“With the speed to start Phase I studies, quality of clinical sites, and a favorable Australian R&D (research and development) tax credit, Australia is an optimal market for early phase clinical research,” Alliance CCO Vito Saccente said. “Alliance will not only be able to provide services critical to this market but also when these compounds move to Phase II, we are well-positioned to transfer methods without losing critical knowledge and can continue to support the progression of clinical development for our clients.”
Alliance has labs in Malvern as well as in the United Kingdom.